About: Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial
Creator	Boff Costa, Marisa Costa, Lucia Da Veiga Picon, Rafael Dorneles Dornelles, Alicia Dornelles Picon, Paulo Felipe, Luis Fendt, Cabral Saccilotto, Indara Schmidt, Carissimi Suksteris, Maurício
source	Medline; PMC
abstract	BACKGROUND: The common cold and other viral airway infections are highly prevalent in the population, and their treatment often requires the use of medications for symptomatic relief. Paracetamol is as an analgesic and antipyretic; chlorphenamine is an antihistamine; and phenylephrine, a vasoconstrictor and decongestant. This randomized, double-blind, placebo-controlled trial sought to evaluate the efficacy and safety of a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine in the symptomatic treatment of the common cold and flu-like syndrome in adults. METHODS: This study enrolled 146 individuals aged 18 to 60 years who had moderate to severe flu-like syndrome or common cold. After clinical examination and laboratory tests, individuals were randomly assigned to receive the fixed-dose combination (73) or placebo (73), five capsules per day for 48 to 72 hours. The primary efficacy endpoint was the sum of the scores of 10 symptoms on a four-point Likert-type scale. To evaluate treatment safety, the occurrence of adverse events was also measured. RESULTS: Mean age was 33.5 (±9.5) years in the placebo group and 33.8 (±11.5) in the treatment group. There were 55 women and 18 men in the placebo group, and 46 women and 27 men in the treatment group. Comparison of overall symptom scores in the two groups revealed a significantly greater reduction in the treatment group than in the placebo group (p = 0.015). Analysis at the first 13 dose intervals (± 66 h of treatment) showed a greater reduction of symptom scores in the treatment group than in the placebo group (p < 0.05). The number and distribution of adverse events were similar in both groups. CONCLUSION: A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more effective than placebo in the symptomatic treatment of the common cold or flu-like syndrome in adults. TRIAL REGISTRATION: NCT01389518
has issue date	2013-11-22(xsd:dateTime)
bibo:doi	10.1186/1471-2334-13-556
bibo:pmid	24261438
has license	cc-by
sha1sum (hex)	2c33d7f0e90a4a8a7e7be1d56308496b7e13dad5
schema:url	https://doi.org/10.1186/1471-2334-13-556
resource representing a document's title	Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial
has PubMed Central identifier	PMC4222817
has PubMed identifier	24261438
schema:publication	BMC Infect Dis
resource representing a document's body	covid:2c33d7f0e90a4a8a7e7be1d56308496b7e13dad5#body_text
is schema:about of	named entity 'PHENYLEPHRINE' named entity 'placebo-controlled trial' named entity 'phenylephrine' named entity 'decongestant' named entity 'The common' named entity 'common cold' named entity 'paracetamol' covid:arg/2c33d7f0e90a4a8a7e7be1d56308496b7e13dad5 named entity 'DOSE' named entity 'HIGHLY' named entity 'USE OF' named entity 'DOSE' named entity 'PHENYLEPHRINE' named entity 'ANTIHISTAMINE' named entity 'COMBINATION' named entity 'THEIR' named entity 'AIRWAY' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'SYMPTOMATIC RELIEF' named entity 'EFFICACY' named entity 'COMMON COLD' named entity 'DOUBLE' named entity 'COMMON COLD' named entity 'INFECTIONS' named entity 'ADULTS' named entity 'FIXED' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'CHLORPHENAMINE' named entity 'RANDOMIZED' named entity 'PARACETAMOL' named entity 'TREATMENT' named entity 'SYMPTOMATIC TREATMENT' named entity 'FIXED' named entity 'PARACETAMOL' named entity 'MEDICATIONS' named entity 'EVALUATE' named entity 'ANALGESIC AND ANTIPYRETIC' named entity 'RANDOMIZED' named entity 'PREVALENT' named entity 'SAFETY' named entity 'CHLORPHENAMINE' named entity 'DECONGESTANT' named entity 'VASOCONSTRICTOR' named entity 'BLIND' named entity 'SYMPTOMATIC TREATMENT' named entity 'COMBINATION' named entity 'POPULATION' named entity 'FLU-LIKE SYNDROME' named entity 'VIRAL' named entity 'efficacy' named entity 'medications' named entity 'common cold' named entity 'highly' named entity 'phenylephrine' named entity 'phenylephrine' named entity 'randomized, placebo-controlled trial' named entity 'phenylephrine' named entity 'Hospital de Clínicas de Porto Alegre' named entity 'symptom' named entity 'nonsteroidal anti-inflammatory drugs' named entity 'tablets' named entity 'adverse effects' named entity 'respiratory syncytial virus' named entity 'paracetamol' named entity 'influenza' named entity 'placebo group' named entity 'treatment group' named entity 'nasal decongestants' named entity 'clinical trial' named entity 'placebo' named entity 'phenylephrine' named entity 'pregnancy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software